|
Market Closed -
London S.E.
10:45:34 2025-11-03 EST
|
After hours 11:25:00 | |||
| 31.92 SEK | -32.03% |
|
0.1540 | -99.52% |
| 08-18 | Seven stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange | FW |
| 08-13 | Immunovia: Strong demand for blood test for pancreatic cancer, survey shows | FW |
Company Valuation: Immunovia AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,697 | 595.2 | 92.66 | 152.7 | 102.4 | - | - |
| Change | - | -64.93% | - | 64.79% | -32.95% | - | - |
| Enterprise Value (EV) 1 | 1,443 | 526.7 | 92.66 | 76.09 | 67.38 | 72.38 | 47.38 |
| Change | - | -63.5% | - | -17.88% | -11.45% | 7.42% | -34.54% |
| P/E | -0.11x | -0.04x | -0.01x | -0.54x | -1.52x | -3.81x | -7.61x |
| PBR | 0.04x | 0.02x | - | - | - | - | - |
| PEG | - | -0.01x | - | 0x | 0x | 0.1x | 0.2x |
| Capitalization / Revenue | 1,775x | 494x | - | 203x | 32x | 5.92x | 1.86x |
| EV / Revenue | 1,510x | 437x | - | 101x | 21.1x | 4.18x | 0.86x |
| EV / EBITDA | -9.78x | -3.17x | - | -0.97x | -0.79x | -0.98x | -1.13x |
| EV / EBIT | -8.66x | -2.76x | - | -0.95x | -0.77x | -0.95x | -1.05x |
| EV / FCF | -9.27x | -2.97x | - | -0.91x | -0.77x | -0.9x | -0.95x |
| FCF Yield | -10.8% | -33.6% | - | -110% | -129% | -111% | -106% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -689 | -743 | -93 | -0.42 | -0.1 | -0.04 | -0.02 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 0.956 | 1.204 | - | 0.752 | 3.2 | 17.3 | 55 |
| EBITDA 1 | -147.6 | -166.2 | - | -78.06 | -85 | -74 | -42 |
| EBIT 1 | -166.6 | -191.2 | - | -80.38 | -88 | -76 | -45 |
| Net income 1 | -156 | -168.1 | -76.54 | -145.9 | -87 | -76 | -45 |
| Net Debt 1 | -254.1 | -68.47 | - | -76.6 | -35 | -30 | -55 |
| Reference price 2 | 75.0000 | 26.3000 | 0.5460 | 0.2270 | 0.1522 | 0.1522 | 0.1522 |
| Nbr of stocks (in thousands) | 22,632 | 22,632 | 169,711 | 672,667 | 672,667 | - | - |
| Announcement Date | 2/17/22 | 2/23/23 | 2/25/25 | 2/24/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 64.75x | 5.07x | 16.95x | 0.33% | 17.87B | |
| 37.88x | - | - | 2.14% | 1.64B | |
| -3.58x | 1.46x | 6.78x | - | 1.01B | |
| 16.41x | 2.32x | 7.77x | 1.43% | 997M | |
| 49.03x | - | - | - | 780M | |
| 148.79x | - | - | 0.6% | 566M | |
| 21.81x | 3.11x | 13.28x | 1.56% | 457M | |
| -11.44x | - | - | - | 441M | |
| Average | 40.46x | 2.99x | 11.19x | 1.21% | 2.97B | |
| Weighted average by Cap. | 57.21x | 4.71x | 15.91x | 0.55% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IMMNOV Stock
- 0G8X Stock
- Valuation Immunovia AB
Select your edition
All financial news and data tailored to specific country editions
